Back to search

Article

siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer Progression

2025-02-08

Abstract excerpt

Lung cancer is the leading cause of tumor-related fatalities worldwide. The current precision therapies are effective but target only those molecules that are impacted in a minority of lung cancer patients. Positive Regulatory Domain 2 (PRDM2), a member of the PRDM gene family, also known as Retinoblastoma Interacting Zinc finger (RIZ) protein. RIZ is found to be misregulated in more than 60% of lung cancer patien...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9c4261dc-6105-516f-afcf-583d6776e0ab
DOI
10.1101/2025.02.06.636957
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer ProgressionDOI 10.1101/2025.02.06.636957
Select a neighboring publication to make it the new centre.